These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Pre-treated anti-PD-1 refractory Merkel cell carcinoma successfully treated with the combination of PD-1/PD-L1 axis inhibitors and TVEC: a report of two cases. Knackstedt R; Sussman TA; McCahon L; Song JM; Funchain P; Gastman B Ann Oncol; 2019 Aug; 30(8):1399-1400. PubMed ID: 31250007 [No Abstract] [Full Text] [Related]
6. Divergent response to PD-L1 inhibition in advanced Merkel cell carcinoma and cutaneous squamous cell carcinoma. Salzmann M; Löser C; Hassel JC J Dtsch Dermatol Ges; 2023 Jul; 21(7):803-805. PubMed ID: 37066606 [No Abstract] [Full Text] [Related]
7. Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers. Komatsubara KM; Jeter J; Carvajal RD; Margolin K; Schadendorf D; Hauschild A Am Soc Clin Oncol Educ Book; 2017; 37():641-650. PubMed ID: 28561682 [TBL] [Abstract][Full Text] [Related]
8. Diffuse lichen planus-like keratoses and clinical pseudo-progression associated with avelumab treatment for Merkel cell carcinoma, a case report. Cardis MA; Jiang H; Strauss J; Gulley JL; Brownell I BMC Cancer; 2019 Jun; 19(1):539. PubMed ID: 31164102 [TBL] [Abstract][Full Text] [Related]
9. Avelumab: A Review of Its Application in Metastatic Merkel Cell Carcinoma. Joseph J; Zobniw C; Davis J; Anderson J; Trinh VA Ann Pharmacother; 2018 Sep; 52(9):928-935. PubMed ID: 29616562 [TBL] [Abstract][Full Text] [Related]
11. Inferior outcomes in immunocompromised Merkel cell carcinoma patients: Can they be overcome by the use of PD1/PDL1 inhibitors? Dasanu CA; Del Rosario M; Codreanu I; Hyams DM; Plaxe SC J Oncol Pharm Pract; 2019 Jan; 25(1):214-216. PubMed ID: 29933728 [TBL] [Abstract][Full Text] [Related]